Shi Fu Chen
Fondateur chez Shenzhen Haplox Biotechnology Co., Ltd.
Profil
Shi Fu Chen is the founder of Shenzhen Haplox Biotechnology Co., Ltd.
where he holds the title of Chief Technology Officer starting in 2014.
He is also the founder of HaploX Investment Holding Ltd.
which was founded in 2021.
At HaploX Investment Holding Ltd., he held the title of Executive Director & Chief Technology Officer.
Currently, Dr. Chen is a Member at the American Society of Clinical Oncology, Inc. Additionally, he obtained a doctorate degree from the Chinese Academy of Sciences in 2008.
Postes actifs de Shi Fu Chen
| Sociétés | Poste | Début |
|---|---|---|
Shenzhen Haplox Biotechnology Co., Ltd.
 Shenzhen Haplox Biotechnology Co., Ltd. BiotechnologyHealth Technology Shenzhen Haplox Biotechnology Co. Ltd. develops clinical application device which helps to detect cancer tumour. The firm’s products cover cancer early screening, individualized drug guidance, prognosis monitoring, drug resistance assessment and provide precision cancer health care for the patients. The company was founded by Shi Fu Chen, Wen Fang, Yuan Wen and Ming Yan Xu on September 12, 2014 and is headquartered in Shenzhen, China. | Fondateur | 01/08/2014 |
American Society of Clinical Oncology, Inc.
 American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Corporate Officer/Principal | - |
Anciens postes connus de Shi Fu Chen
| Sociétés | Poste | Fin |
|---|---|---|
HaploX Investment Holding Ltd.
 HaploX Investment Holding Ltd. Miscellaneous Commercial ServicesCommercial Services HaploX Investment Holding Ltd. engages in the provision of genetic testing solutions with a focus on using molecular diagnostics technologies. It offers genetic testing results that enable full cycle health management for cancer and other patients as well as health screening and risk assessment for individuals, genetic testing of pathogenic microbes, and other pathogens, to research and development genetic testing primarily for biopharmaceutical companies and research institutes. The company was founded by Ming Yan Xu, Yuan Wen, Shi Fu Chen, and Wen Fang on November 29, 2021 and is headquartered in Hong Kong. | Fondateur | - |
Formation de Shi Fu Chen
| Chinese Academy of Sciences | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Shenzhen Haplox Biotechnology Co., Ltd.
Shenzhen Haplox Biotechnology Co., Ltd. BiotechnologyHealth Technology Shenzhen Haplox Biotechnology Co. Ltd. develops clinical application device which helps to detect cancer tumour. The firm’s products cover cancer early screening, individualized drug guidance, prognosis monitoring, drug resistance assessment and provide precision cancer health care for the patients. The company was founded by Shi Fu Chen, Wen Fang, Yuan Wen and Ming Yan Xu on September 12, 2014 and is headquartered in Shenzhen, China. | Health Technology |
HaploX Investment Holding Ltd.
HaploX Investment Holding Ltd. Miscellaneous Commercial ServicesCommercial Services HaploX Investment Holding Ltd. engages in the provision of genetic testing solutions with a focus on using molecular diagnostics technologies. It offers genetic testing results that enable full cycle health management for cancer and other patients as well as health screening and risk assessment for individuals, genetic testing of pathogenic microbes, and other pathogens, to research and development genetic testing primarily for biopharmaceutical companies and research institutes. The company was founded by Ming Yan Xu, Yuan Wen, Shi Fu Chen, and Wen Fang on November 29, 2021 and is headquartered in Hong Kong. | Commercial Services |
American Society of Clinical Oncology, Inc.
American Society of Clinical Oncology, Inc. Medical/Nursing ServicesHealth Services The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research. | Health Services |